16.55
0.20 (1.22%)
| Previous Close | 16.35 |
| Open | 16.42 |
| Volume | 725,295 |
| Avg. Volume (3M) | 1,744,715 |
| Market Cap | 1,198,026,624 |
| Price / Earnings (TTM) | 13.57 |
| Price / Earnings (Forward) | 87.72 |
| Price / Sales | 43.42 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Diluted EPS (TTM) | -3.04 |
| Current Ratio (MRQ) | 1.16 |
| Operating Cash Flow (TTM) | -142.86 M |
| Levered Free Cash Flow (TTM) | -102.50 M |
| Return on Assets (TTM) | -30.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Omeros Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.00 |
Select this tab to load the latest available analysis.
|
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.40% |
| % Held by Institutions | 47.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rock Springs Capital Management Lp | 30 Jun 2026 | 718,499 |
| Corient Private Wealth Lp | 30 Jun 2026 | 659,730 |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |